2020年6月24日 · Here we show that IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.

2024年12月25日 · IL18BP (Interleukin 18 Binding Protein) is a Protein Coding gene. Diseases associated with IL18BP include Hepatitis, Fulminant Viral and Molluscum Contagiosum. Among its related pathways are IL-1 Family Signaling Pathways and Cytokine Signaling in Immune system.

IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β.

IL-18 binding protein (IL-18BP) is a natural regulatory molecule of the proinflammatory cytokine IL-18. It can regulate activity of IL-18 by high affinity binding. The present review aimed to highlight developments, characteristics and functions of IL-18BP. IL-18BP serves biological and anti-pathological roles in treating disease.

2013年10月7日 · The IL-18BP has been used safely in humans and clinical trials of IL-18BP as well as neutralizing anti-IL-18 antibodies are in clinical trials. This review updates the biology of IL-18 as well as its role in human disease.

2024年12月17日 · IL-18 Binding Protein (IL-18BP) is one of only four natural cytokine antagonists encoded by a separate gene, distinguishing it from canonical soluble receptors.

IL-18 is negatively regulated by a decoy receptor called IL-18 binding protein (IL-18BP), a secreted antagonist that binds IL-18 with extremely high affinity (KD < 1nM)10. In patients treated with rIL-18, serum IL-18BP concentrations increased by 10 to 100-fold9,11.

2023年12月11日 · IL-18 binding protein is a valuable biomarker of IFNγ activity. IL-18-mediated pathology includes multiple organs and systems, particularly systemic hyperinflammation, which is consistent...

In an effort to identify alternative cytokine pathways for immunotherapy, we found that components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity.

2020年8月18日 · In a new study in Nature, Zhou et al. identify IL-18BP as a novel soluble immune checkpoint, and describe engineering of a decoy-resistant IL-18 to overcome this barrier and drive potent...